TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Depressive Symptoms in Physically Ill Youth
Brief Summary: Children and adolescents with inflammatory bowel disease (IBD) have high rates of depressive symptoms and more trouble with daily functioning than those without physical illness. The proposed study will investigate if cognitive behavioral therapy (CBT) is better than supportive therapy (SNDT) in reducing emotional distress and improving functioning in youth ages 9-17 with Crohn's disease or Ulcerative Colitis and depression. This study will also assess the effect of CBT on IBD-related factors such as disease severity, medication adherence, and physical-health related quality of life.

Hypothesis

- Individuals who receive CBT will show more improvement than individuals who receive SNDT.


Options:
A: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
B: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Supportive Non-Directive Therapy (SNDT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Non-directive Therapy (SNDT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Supportive Non-directive Therapy (SNDT); Assigned to Arm(s): Supportive Non-Directive Therapy (SNDT)
C: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Standard of Community Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Community Care Treatment | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Standard of Community Care Treatment; Assigned to Arm(s): Standard of Community Care Treatment
D: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outcome After Anterior Vaginal Prolapse Repair: A Randomized Controlled Trial
Brief Summary: The purpose of this study is determine whether grafted anterior vaginal prolapse repair is more effective and associated with less complications than prolapse repair with suture.


Options:
A: Arm Label: Polypropylene Mesh; Type: ACTIVE_COMPARATOR; Interventions: Device: Polypropylene mesh (Polyform by Boston Scientific) | Arm Label: Anterior Colporrhaphy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Anterior Colporrhaphy | Arm Label: Porcine Dermis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Porcine Dermis (Pelvicol by CRBard) | Intervention Type: DEVICE; Name: Polypropylene mesh (Polyform by Boston Scientific); Assigned to Arm(s): Polypropylene Mesh | Intervention Type: PROCEDURE; Name: Porcine Dermis (Pelvicol by CRBard); Assigned to Arm(s): Porcine Dermis | Intervention Type: PROCEDURE; Name: Anterior Colporrhaphy; Assigned to Arm(s): Anterior Colporrhaphy
B: Arm Label: Anterior Colporrhaphy (sutured repair); Type: PLACEBO_COMPARATOR; Interventions: Procedure: sutured anterior vaginal prolapse repair | Arm Label: Perigee (grafted repair); Type: ACTIVE_COMPARATOR; Interventions: Device: grafted anterior prolapse repair | Intervention Type: DEVICE; Name: grafted anterior prolapse repair; Assigned to Arm(s): Perigee (grafted repair) | Intervention Type: PROCEDURE; Name: sutured anterior vaginal prolapse repair; Assigned to Arm(s): Anterior Colporrhaphy (sutured repair)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Avaulta (surgical procedure using a mesh implant) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional surgery (anterior repair) | Intervention Type: PROCEDURE; Name: Avaulta (surgical procedure using a mesh implant); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional surgery (anterior repair); Assigned to Arm(s): 2
D: Arm Label: Intervention: Collagen matrix; Type: EXPERIMENTAL; Interventions: Procedure: Collagen Matrix | Arm Label: Native tissue repair; Type: OTHER; Interventions: Procedure: Collagen Matrix | Intervention Type: PROCEDURE; Name: Collagen Matrix; Assigned to Arm(s): Intervention: Collagen matrix, Native tissue repair

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outcome After Anterior Vaginal Prolapse Repair: A Randomized Controlled Trial
Brief Summary: The purpose of this study is determine whether grafted anterior vaginal prolapse repair is more effective and associated with less complications than prolapse repair with suture.


Options:
A: Arm Label: Anterior Colporrhaphy (sutured repair); Type: PLACEBO_COMPARATOR; Interventions: Procedure: sutured anterior vaginal prolapse repair | Arm Label: Perigee (grafted repair); Type: ACTIVE_COMPARATOR; Interventions: Device: grafted anterior prolapse repair | Intervention Type: DEVICE; Name: grafted anterior prolapse repair; Assigned to Arm(s): Perigee (grafted repair) | Intervention Type: PROCEDURE; Name: sutured anterior vaginal prolapse repair; Assigned to Arm(s): Anterior Colporrhaphy (sutured repair)
B: Arm Label: Mesh surgery; Type: EXPERIMENTAL; Interventions: Device: Tensionfree vaginal mesh kit (Prolift) | Arm Label: Conventional vaginal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: classic vaginal prolapse surgery (fascia plication) | Intervention Type: DEVICE; Name: Tensionfree vaginal mesh kit (Prolift); Assigned to Arm(s): Mesh surgery | Intervention Type: PROCEDURE; Name: classic vaginal prolapse surgery (fascia plication); Assigned to Arm(s): Conventional vaginal surgery
C: N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Avaulta (surgical procedure using a mesh implant) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional surgery (anterior repair) | Intervention Type: PROCEDURE; Name: Avaulta (surgical procedure using a mesh implant); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional surgery (anterior repair); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
Brief Summary: The purpose of this study is to determine if using an electronic reminder improves adherence to sunscreen use. The specific study aims are as follows:

1. To determine whether the use of electronic reminder system increases adherence to topical agents.
2. To assess technological feasibility of measuring adherence to topical agents using electronic monitors specially designed for tubes.
3. To assess technological feasibility of providing electronic reminders using cellular phone text-messaging system.
4. To obtain subjects' feedback on the adherence monitoring and reminder system.


Options:
A: Arm Label: Paper food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Paper food diary | Arm Label: Online food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online food diary | Arm Label: "My Meal Mate" (smartphone application); Type: EXPERIMENTAL; Interventions: Behavioral: "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: "My Meal Mate" (smartphone application); Assigned to Arm(s): "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: Paper food diary; Assigned to Arm(s): Paper food diary | Intervention Type: BEHAVIORAL; Name: Online food diary; Assigned to Arm(s): Online food diary
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic Self-Report Assessment - Cancer (ESRA-C); Assigned to Arm(s): Intervention
C: Arm Label: Paper-based screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: E-screening; Type: EXPERIMENTAL; Interventions: Other: E-screening | Intervention Type: OTHER; Name: E-screening; Assigned to Arm(s): E-screening
D: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
Brief Summary: The purpose of this study is to determine if using an electronic reminder improves adherence to sunscreen use. The specific study aims are as follows:

1. To determine whether the use of electronic reminder system increases adherence to topical agents.
2. To assess technological feasibility of measuring adherence to topical agents using electronic monitors specially designed for tubes.
3. To assess technological feasibility of providing electronic reminders using cellular phone text-messaging system.
4. To obtain subjects' feedback on the adherence monitoring and reminder system.


Options:
A: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message
B: Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: Standard Care | Arm Label: Sustained Care; Type: EXPERIMENTAL; Interventions: Behavioral: Sustained Care | Intervention Type: BEHAVIORAL; Name: Sustained Care; Assigned to Arm(s): Sustained Care | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard care
C: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
D: Arm Label: Traditional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine Education Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education | Arm Label: Telemedicine IVR Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: IVR | Arm Label: Telemedicine Both Pathway; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine Education, Behavioral: IVR | Intervention Type: BEHAVIORAL; Name: Telemedicine Education; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine Education Pathway | Intervention Type: BEHAVIORAL; Name: IVR; Assigned to Arm(s): Telemedicine Both Pathway, Telemedicine IVR Pathway

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.
Brief Summary: Primary Objective:

* To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older.

Secondary Objective:

* To assess the tolerability of lenalidomide in patients with untreated CLL age 65 and older


Options:
A: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide
B: Arm Label: IBR + OB; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Obinutuzumab | Arm Label: CLB + OB; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): IBR + OB | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): CLB + OB, IBR + OB | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): CLB + OB
C: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil
D: Arm Label: Bendamustine + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Venetoclax + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Bendamustine + Rituximab Crossover Substudy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Venetoclax + Rituximab Re-Treatment; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine + Rituximab, Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Depression in Patients Being Treated for Head and Neck Cancer
Brief Summary: This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.


Options:
A: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Problem Solving Treatment; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2
D: Arm Label: Citalopram; Type: EXPERIMENTAL; Interventions: Drug: 20mg daily citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 20mg daily citalopram; Assigned to Arm(s): Citalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Deficiency in Acutely Injured Pediatric Burn Patients: Incidence, Etiology, Metabolic Sequelae and Prevention
Brief Summary: To see which vitamin D supplement (D2 vs D3) is most beneficial in burned children.


Options:
A: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D3
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D2; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): N/A
C: Arm Label: Maternal and Neonatal Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Maternal and Neonatal Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Maternal and Neonatal Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Maternal and Neonatal Control Arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D, cholecalciferol; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.
Brief Summary: This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: SPM 907; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: ONO-8025 (KRP-197); Assigned to Arm(s): N/A
D: Arm Label: Fesoterodine (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Double-Blind)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Cetuximab to Evaluate the Efficacy in Patients With Locally Advanced or Metastatic EGFR-EGFR-Positive Pancreatic Cancer. SpaCe Trial
Brief Summary: This is multicenter, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Primary objective: objective response rate. Secondary objectives: safety, time to disease progression, median duration of response, time to treatment failure, overall survival time, correlation between bio-pathological characterization (EGFR, akt, MAPks) objective response and survival


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B
B: Arm Label: Folfirinox; Type: EXPERIMENTAL; Interventions: Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin | Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine hydrochloride | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Gemcitabine | Intervention Type: DRUG; Name: irinotecan hydrochloride; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): Folfirinox | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Folfirinox
C: Arm Label: A; Type: NO_INTERVENTION; Interventions: Genetic: cetuximab | Intervention Type: GENETIC; Name: cetuximab; Assigned to Arm(s): A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+erlotinib | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine+erlotinib+capecitabine | Intervention Type: DRUG; Name: Gemcitabine+erlotinib; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Gemcitabine+erlotinib+capecitabine; Assigned to Arm(s): Experimental

Answer: C